Weekender 7/17/15

To Our New Jersey Life Sciences Community:

Welcome to another edition of the Weekender.

Another Great Week for New Jersey Approvals

Basking Ridge-based BioNJ Member Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the FDA has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. Dysport® was previously approved for the treatment of adults with cervical dystonia (CD) in April 2009.

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the FDA approved REXULTI® (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia. It is expected to become available to patients in the U.S. in early August 2015.

Princeton-based BioNJ Member Bristol-Myers Squibb Company announced that the European Commission has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir. The U.S. Food and Drug Administration approved Evotaz in January 2015.

Galderma announced that the Food and Drug Administration (FDA) has approved Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% for the once-daily topical treatment of acne vulgaris.

BioNJ Members Featured in This Week’s News:

Congratulations to George Golumbeski, Senior Vice President, Business Development, Celgene, who was featured on the cover of Life Science Leader Magazine; Christian Kopfli, CEO, Chromocell, featured in NJBiz for his leadership and Panna Sharma, CEO, Cancer Genetics Inc., who was spotlighted in a new series, Becoming CEO, for taking CGI to a whole new level!
Thank You to Our New Jersey Representatives

Congress is currently considering H.R. 9, The Innovation Act. It is a bipartisan effort to produce reform in the patent system, but BioNJ believes that it does not provide the protection that legitimate patent holders needWe would like to thank New Jersey Representatives who signed a patent reform letter which addresses industry concerns, including Donald Norcross (D-1), Tom MacArthur (R-3), Christopher Smith (R-4), Leonard Lance (R-7), Albio Sires (D-8), Bill Pascrell, Jr. (D-9), Donald Payne Jr. (D-10) and Bonnie Watson Coleman (D-12). Click here for a copy of the letter.


Record-Breaking Attendance for BioCruise

Thank you to everyone who joined BioNJ and NewYork BIO for the Newx2 BioCruise, that took place this Wednesday on the New York Harbor. We had nearly 200 life sciences professionals on board for an evening of networking, amazing scenery and great fun!

 Make sure to register for the BioNJ/LES Summer Bar-B-Que taking place on July 28 at the Basking Ridge Country Club!

Click here for this week’s Weekender.